You just read:

CytRx Announces the Completion of Enrollment in Its Global Phase 2b Clinical Trial of Aldoxorubicin in Patients with Second-Line Small Cell Lung Cancer

News provided by

CytRx Corporation

Sep 07, 2016, 09:00 ET